JP2016526909A5 - - Google Patents

Download PDF

Info

Publication number
JP2016526909A5
JP2016526909A5 JP2016531860A JP2016531860A JP2016526909A5 JP 2016526909 A5 JP2016526909 A5 JP 2016526909A5 JP 2016531860 A JP2016531860 A JP 2016531860A JP 2016531860 A JP2016531860 A JP 2016531860A JP 2016526909 A5 JP2016526909 A5 JP 2016526909A5
Authority
JP
Japan
Prior art keywords
polypeptide
cysteine
substituted
amino acid
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016531860A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016526909A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/048908 external-priority patent/WO2015017548A2/en
Publication of JP2016526909A publication Critical patent/JP2016526909A/ja
Publication of JP2016526909A5 publication Critical patent/JP2016526909A5/ja
Priority to JP2020160475A priority Critical patent/JP7344858B2/ja
Pending legal-status Critical Current

Links

JP2016531860A 2013-07-31 2014-07-30 Fc含有ポリペプチドの安定化 Pending JP2016526909A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2020160475A JP7344858B2 (ja) 2013-07-31 2020-09-25 Fc含有ポリペプチドの安定化

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361860800P 2013-07-31 2013-07-31
US61/860,800 2013-07-31
PCT/US2014/048908 WO2015017548A2 (en) 2013-07-31 2014-07-30 Stabilization of fc-containing polypeptides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020160475A Division JP7344858B2 (ja) 2013-07-31 2020-09-25 Fc含有ポリペプチドの安定化

Publications (2)

Publication Number Publication Date
JP2016526909A JP2016526909A (ja) 2016-09-08
JP2016526909A5 true JP2016526909A5 (enExample) 2017-09-07

Family

ID=52432568

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016531860A Pending JP2016526909A (ja) 2013-07-31 2014-07-30 Fc含有ポリペプチドの安定化
JP2020160475A Active JP7344858B2 (ja) 2013-07-31 2020-09-25 Fc含有ポリペプチドの安定化

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020160475A Active JP7344858B2 (ja) 2013-07-31 2020-09-25 Fc含有ポリペプチドの安定化

Country Status (15)

Country Link
US (3) US20160193295A1 (enExample)
EP (1) EP3027647A4 (enExample)
JP (2) JP2016526909A (enExample)
KR (3) KR20160034404A (enExample)
CN (1) CN105658664A (enExample)
AU (3) AU2014296215A1 (enExample)
BR (1) BR112016002219A2 (enExample)
CA (1) CA2919076C (enExample)
CL (1) CL2016000232A1 (enExample)
EA (1) EA035319B1 (enExample)
HK (1) HK1224203A1 (enExample)
IL (1) IL243690B (enExample)
MX (2) MX2016001165A (enExample)
SG (1) SG11201600734YA (enExample)
WO (1) WO2015017548A2 (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2862516C (en) 2012-03-27 2023-02-14 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
WO2014120619A2 (en) 2013-01-30 2014-08-07 Ngm Biopharmaceuticals, Inc. Compositions and methods of use in treating metabolic disorders
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
FR3012453B1 (fr) 2013-10-31 2015-11-13 Lab Francais Du Fractionnement Proteine chimerique dans le traitement de l’amylose
UA123432C2 (uk) 2014-07-30 2021-04-07 Нджм Біофармасьютікалз, Інк. Димер та спосіб його застосування для лікування метаболічних розладів
ES2799503T3 (es) * 2014-10-31 2020-12-18 Ngm Biopharmaceuticals Inc Composiciones y procedimientos de uso para el tratamiento de trastornos metabólicos
WO2016100788A1 (en) 2014-12-19 2016-06-23 Alkermes, Inc. Single chain fc fusion proteins
IL256989B (en) 2015-08-07 2022-08-01 Alx Oncology Inc Constructs with a sirp-alpha site or a variant thereof
CA3025162A1 (en) 2016-05-26 2017-11-30 Qilu Puget Sound Biotherapeutics Corporation Mixtures of antibodies
CA3026393C (en) 2016-06-22 2023-03-14 Alkermes, Inc. Compositions and methods for modulating il-10 immunostimulatory and anti-inflammatory properties
MX2019007611A (es) * 2016-12-22 2020-07-29 Cue Biopharma Inc Polipéptidos multiméricos moduladores de linfocitos t y métodos para su uso.
EP3576789B1 (en) * 2017-02-01 2024-12-11 Zhejiang Shimai Pharmaceutical Co., Ltd. MONOMERIC HUMAN IgG1 Fc AND BISPECIFIC ANTIBODIES
IL271837B2 (en) * 2017-07-07 2024-01-01 Hanmi Pharm Ind Co Ltd Novel therapeutic enzyme fusion protein and use thereof
CA3071337A1 (en) * 2017-08-15 2019-02-21 Kindred Biosciences, Inc. Igg fc variants for veterinary use
CN107540748B (zh) * 2017-09-15 2020-07-14 北京伟杰信生物科技有限公司 长效重组猪fsh融合蛋白及其制备方法与应用
US12435328B2 (en) * 2017-12-22 2025-10-07 Hanmi Pharm. Co., Ltd. Therapeutic enzyme fusion protein having a novel structure and use thereof
TWI724392B (zh) 2018-04-06 2021-04-11 美商美國禮來大藥廠 生長分化因子15促效劑化合物及其使用方法
CN109021109A (zh) * 2018-07-20 2018-12-18 上海交通大学 一种牛源性抗金黄色葡萄球菌融合抗体scFv-Fc及其制备方法
KR20210042117A (ko) 2018-08-03 2021-04-16 암젠 리서치 (뮌헨) 게엠베하 Cldn18.2 및 cd3에 대한 항체 작제물
KR102148405B1 (ko) * 2018-09-19 2020-08-27 주식회사 바이오앱 돼지의 Fc 단편을 포함하는 재조합 벡터 및 상기 벡터를 이용한 재조합 단백질의 제조 방법
KR102200773B1 (ko) * 2018-09-19 2021-01-12 주식회사 바이오앱 돼지의 Fc 단편과 융합된 항원 및 이를 포함하는 백신 조성물
US10947278B2 (en) * 2018-09-19 2021-03-16 Bioapplications Inc. Recombinant vector comprising porcine FC fragment and preparation method of recombinant protein using thereof
WO2020167957A1 (en) * 2019-02-12 2020-08-20 Board Of Regents, The University Of Texas System High affinity engineered t-cell receptors targeting cmv infected cells
KR20220044904A (ko) 2019-05-31 2022-04-12 알렉소 온콜로지 인크. 면역 관문 억제제와 병용하는 sirp 알파 fc 융합으로 암을 치료하는 방법
JP7661245B2 (ja) 2019-06-07 2025-04-14 アムジエン・インコーポレーテツド 二重特異性結合構築物
WO2021053556A1 (en) * 2019-09-18 2021-03-25 Novartis Ag Nkg2d fusion proteins and uses thereof
US11542276B2 (en) 2019-11-25 2023-01-03 Alkermes, Inc. Substituted macrocyclic compounds and related methods of treatment
AU2020400805B2 (en) * 2019-12-11 2024-03-28 Lg Chem, Ltd. Fusion polypeptide comprising GDF15 and polypeptide region capable of O-glycosylation
US20230093169A1 (en) 2020-01-22 2023-03-23 Amgen Research (Munch) Gmbh Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
JP7481856B2 (ja) * 2020-02-25 2024-05-13 シスメックス株式会社 改変抗体及びその製造方法、並びに抗体の熱安定性を向上させる方法
CN111285936A (zh) * 2020-03-11 2020-06-16 北京双赢科创生物科技有限公司 靶向肿瘤的酸性敏感纳米肽段及其应用
TW202200615A (zh) 2020-03-12 2022-01-01 美商安進公司 用於治療和預防患者的crs之方法
JP2023527293A (ja) 2020-05-19 2023-06-28 アムジエン・インコーポレーテツド Mageb2結合構築物
CN116096736A (zh) * 2020-08-14 2023-05-09 武汉友微生物技术有限公司 新型冠状病毒rbd融合蛋白
US20230322860A1 (en) * 2020-08-21 2023-10-12 Ajou University Industry-Academic Cooperation Foundation ANTIBODY FRAGMENT CONSISTING OF HEAVY CHAIN AND LIGHT CHAIN CONSTANT REGIONS IN WHICH GAMMA CONSTANT REGION (Cgamma1) AND EPSILON CONSTANT REGION (CE2-4) ARE FUSED, AND USE THEREOF
CN114426974B (zh) * 2020-10-29 2023-11-21 洛阳普泰生物技术有限公司 特异性结合非洲猪瘟病毒CD2v蛋白的抗体或抗体片段
KR20230097061A (ko) * 2020-11-02 2023-06-30 아트라러스, 인크. Sap fc 융합 단백질 및 사용 방법
TW202233679A (zh) 2020-11-06 2022-09-01 德商安美基研究(慕尼黑)公司 選擇性地與cldn6和cd3結合的多肽構建體
JP2023552375A (ja) * 2020-12-06 2023-12-15 エーエルエックス オンコロジー インコーポレイテッド 血清学的アッセイにおいてcd47に結合する薬物の干渉を低減するための多量体
US11760747B2 (en) 2020-12-21 2023-09-19 Alkermes, Inc. Substituted piperidino compounds and related methods of treatment
CA3216908A1 (en) 2021-05-13 2022-11-17 ALX Oncology Inc. Combination therapies for treating cancer
EP4392461A4 (en) * 2021-08-24 2025-10-15 Sunshine Lake Pharma Co Ltd GDF15 FUSION PROTEINS AND THEIR USES
CN116064562A (zh) * 2022-10-28 2023-05-05 江南大学 玉米赤霉烯酮的真核表达单链抗体以及全长抗体的制备方法以及用途
CN116284455B (zh) * 2023-04-17 2024-10-11 北京康乐卫士生物技术股份有限公司 一种带状疱疹病毒疫苗的嵌合抗原及其应用
WO2025036564A1 (de) * 2023-08-17 2025-02-20 Gottfried Wilhelm Leibniz Universität Hannover (Luh) Nukleinsäuresequenz, vektor, screening-verfahren und verfahren zur herstellung von rekombinanten antikörpern
WO2025162458A1 (zh) * 2024-02-04 2025-08-07 南通壹宸生物医药科技有限公司 融合抗体及其制备和应用
CN118344462B (zh) * 2024-06-18 2024-11-08 苏州易合医药有限公司 一种用于肺部给药的索马鲁肽突变体、融合蛋白及相关产品
CN119613573B (zh) * 2025-02-14 2025-05-30 浙江大学 一种CD40L-Fc融合蛋白、基因片段、重组质粒、重组细胞以及制备方法和用途
CN119735654B (zh) * 2025-02-27 2025-07-01 浙江海隆生物科技股份有限公司 一种牛副流感病毒的亚单位hn蛋白制备方法和应用
CN120623322B (zh) * 2025-08-14 2025-12-05 成都蓉生药业有限责任公司 一种人IgG Fc变体、基因片段、表达载体、宿主细胞、IgG抗体及人IgG Fc变体制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7951917B1 (en) * 1997-05-02 2011-05-31 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
ES2246069T3 (es) * 1997-05-02 2006-02-01 Genentech, Inc. Procedimiento de preparacion de anticuerpos multiespecificos que tienen componentes comunes y multimericos.
US20030207346A1 (en) * 1997-05-02 2003-11-06 William R. Arathoon Method for making multispecific antibodies having heteromultimeric and common components
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US7754209B2 (en) * 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
AU2005282700A1 (en) * 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
EA016609B1 (ru) * 2005-11-28 2012-06-29 Генмаб А/С Рекомбинантные моновалентные антитела и способы их получения
JP2013511281A (ja) * 2009-11-23 2013-04-04 アムジェン インコーポレイテッド 単量体抗体Fc
MX379481B (es) 2010-12-06 2025-03-11 Seagen Inc Anticuerpos humanizados a liv-1 y uso de los mismos para tratar cancer

Similar Documents

Publication Publication Date Title
JP2016526909A5 (enExample)
ZA202409972B (en) Fcrn antagonists and methods of use
JP2017512063A5 (enExample)
EP4417624A3 (en) Antibodies comprising chimeric constant domains
EA201190326A1 (ru) Полипептиды гормона роста и способы их получения и применения
JP2017509335A5 (enExample)
HRP20220960T1 (hr) Kimerni proteini faktora viii i njihova upotreba
JP2015514423A5 (enExample)
MX2017006866A (es) Pares de unión para producción de péptidos.
PH12020551134A1 (en) Fc variants with enhanced binding to fcrn and prolonged half-life
EA201690299A1 (ru) СТАБИЛИЗАЦИЯ Fc-СОДЕРЖАЩИХ ПОЛИПЕПТИДОВ
WO2015023891A3 (en) Factor viii-xten fusions and uses thereof
EA201790976A1 (ru) Терапевтические вакцины против hpv16
WO2013142859A3 (en) Fusion proteins of superfolder green fluorescent protein and use thereof
RU2017132689A (ru) СЛИТАЯ С Fc α-ЦЕПЬ ВЫСОКОАФФИННОГО РЕЦЕПТОРА IgE
EA201791238A1 (ru) Способы и композиции, в которых используются варианты полипептидов klotho
EA201691548A1 (ru) Экспрессирующие конструкции и способы для отбора клеток-хозяев, экспрессирующих полипептиды
UA117493C2 (uk) Гібридна конструкція, що включає антигенсполучний фрагмент, специфічний до сироваткового альбуміну, й ефекторний компонент, та способи її одержання
JP2017061471A5 (enExample)
GB2543713A (en) Polymeric proteins and uses thereof
NZ760008A (en) Uti fusion proteins
JP2017526625A5 (enExample)
CA3249454A1 (en) Constant domains of chimeric heavy chain having a reduced link to gamma FC receptors and their uses
MY209502A (en) N-terminal extension sequence for expression of recombinant therapeutic peptides
RU2014137557A (ru) Способ получения биологически активных пептидов